

**Filed On Behalf Of:**  
Novartis AG

**By:**  
Nicholas N. Kallas  
NKallas@fchs.com  
ZortressAfinitorIPR@fchs.com  
(212) 218-2100

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

PAR PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS AG,

Patent Owner.

---

Case IPR2016-01479

Patent No. 9,006,224

---

**PATENT OWNER'S EXHIBIT LIST 1**

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2001</b>	Expert Declaration Of Matthew H. Kulke, M.D., M.M.Sc.	<b>Kulke Decl.</b>
<b>2002</b>	<i>Curriculum Vitae</i> of Matthew H. Kulke, M.D., M.M.Sc.	<b>Kulke C.V.</b>
<b>2003</b>	Seeley, R. R., Stephens, T.D., & Tate, P., <i>Anatomy &amp; Physiology</i> , 3rd Edition, pages 585 – 586 (1995)	<b>Seeley</b>
<b>2004</b>	<i>Reserved</i>	
<b>2005</b>	Laughlin, E.H., <i>Coming To Terms With Cancer: A Glossary Of Cancer-Related Terms</i> , page 4 (2002)	<b>Laughlin Cancer Glossary</b>
<b>2006</b>	<i>Reserved</i>	
<b>2007</b>	<i>Reserved</i>	
<b>2008</b>	Motzer, R.J. & Russo, P., “Systemic Therapy For Renal Cell Carcinoma,” <i>J. Urology</i> 163:408-417 (2000)	<b>Motzer</b>
<b>2009</b>	<i>Reserved</i>	

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2010</b>	Pazdur, R., <i>et al.</i> (eds.), Chapters 6, 11, 14-16, 19, 25, <i>Cancer Management: A Multidisciplinary Approach: Medical, Surgical, &amp; Radiation Oncology</i> , 9th Edition (2005)	<b>Pazdur</b>
<b>2011</b>	Kouvaraki, M.A. <i>et al.</i> , “Fluorouracil, Doxorubicin, And Streptozocin In The Treatment Of Patients With Locally Advanced And Metastatic Pancreatic Endocrine Carcinomas,” <i>J. Clin. Oncol.</i> 22(23):4762-4771 (2004)	<b>Kouvaraki</b>
<b>2012</b>	Delaunoy, Th., <i>et al.</i> , “The Doxorubicin-Streptozotocin Combination For The Treatment Of Advanced Well-Differentiated Pancreatic Endocrine Carcinoma: A Judicious Option?,” <i>Eur. J. Cancer</i> 40:515-520 (2004)	<b>Delaunoy</b>
<b>2013</b>	Kulke, M.H., Chapter 110, “Neuroendocrine Cancer,” <i>Clinical Hematology and Oncology: Presentation, Diagnosis and Treatment</i> (Furie, B., <i>et al.</i> eds. 2003)	<b>Kulke 2003</b>
<b>2014</b>	Kulke, M.H. <i>et al.</i> , “A Phase II Trial Of Gemcitabine For Metastatic Neuroendocrine Tumors,” <i>Cancer</i> 101(5): 934-939 (2004)	<b>Kulke 2004</b>

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2015</b>	Margolin, K. <i>et al.</i> , "CCI-779 In Metastatic Melanoma: A Phase II Trial Of The California Cancer Consortium," <i>Cancer</i> 104(5): 1045-1048 (2005)	<b>Margolin</b>
<b>2016</b>	"Novartis Drug Afinitor Is First Treatment For Advanced Pancreatic NET To Provide Overall Survival Of More Than 3.5 Years In Phase III Trial," <i>Novartis Institutes For Biomedical Research</i> (September 27, 2014)	<b>Novartis Press Release</b>
<b>2017</b>	Ritschel, W.A., <i>Handbook of Basic Pharmacokinetics</i> , 4th Edition, pages 6-7, 264-267 (1992)	<b>Ritschel</b>
<b>2018</b>	Heitz, Ph.U., <i>et al.</i> , Chapter 4, "Tumours Of The Endocrine Pancreas," <i>World Health Organization Classification of Tumours, Pathology and Genetics, Tumours of Endocrine Organs</i> , pages 177-182 (DeLellis, R.A. <i>et al.</i> , eds. 2004)	<b>WHO</b>
<b>2019</b>	Physicians' Desk Reference, 59th Edition (2005), pages 1844-1849 (Entry for Gemzar®(Gemcitabine HCl))	<b>Gemzar® Prescribing Information 2005</b>
<b>2020</b>	Kulke, M.H. & Mayer, R.J., "Carcinoid Tumors," <i>N. Eng. J. Med.</i> 340(11): 858-868 (1999)	<b>Kulke 1999</b>

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2021</b>	Gennaro, A.R. (Ed.), <i>Remington's</i> , 18th Edition, pages 726-730 (1990)	<b>Remington's</b>
<b>2022</b>	Yao, J.C. <i>et al.</i> , "Everolimus For Advanced Pancreatic Neuroendocrine Tumors," <i>N. Eng. J. Med.</i> 364(6): 514-523 (2011)	<b>Yao</b>
<b>2023</b>	Kola, I. & Landis, J., "Can The Pharmaceutical Industry Reduce Attrition Rates?," <i>Nat. Rev. Drug Discov.</i> , 3:711-715 (2004)	<b>Kola &amp; Landis</b>
<b>2024</b>	Excerpts of Transcript of Trial Testimony of M. Ratain, <i>Pfizer Inc. et al. v. Mylan Pharms. Inc.</i> , (C.A. No. 10-528-GMS), (D. Del. November 29, 2012), Pages 778-79, 950, 995	<b>Ratain Trial Tr. I</b>
<b>2025</b>	Excerpts of Transcript of Trial Testimony of M. Ratain, <i>Novartis v. Breckenridge, Roxane and Par</i> (C.A. Nos. 14-1043-RGA, 14-1196-RGA and 14-1289-RGA) (D. Del. August 31, 2016), Pages 769-772, 957, 993-94, 1003, 1010, 1012, 1014	<b>Ratain Trial Tr. II</b>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.